Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/55169
Full metadata record
DC FieldValueLanguage
dc.contributor.authorP. Tanajaken_US
dc.contributor.authorP. Sa-Nguanmooen_US
dc.contributor.authorX. Wangen_US
dc.contributor.authorG. Liangen_US
dc.contributor.authorX. Lien_US
dc.contributor.authorC. Jiangen_US
dc.contributor.authorS. C. Chattipakornen_US
dc.contributor.authorN. Chattipakornen_US
dc.date.accessioned2018-09-05T02:52:40Z-
dc.date.available2018-09-05T02:52:40Z-
dc.date.issued2016-08-01en_US
dc.identifier.issn17481716en_US
dc.identifier.issn17481708en_US
dc.identifier.other2-s2.0-84979021421en_US
dc.identifier.other10.1111/apha.12698en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84979021421&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/55169-
dc.description.abstract© 2016 Scandinavian Physiological Society. Published by John Wiley & Sons Ltd Fibroblast growth factor 21 (FGF21) acts as a metabolic regulator and exerts cardioprotective effects. However, the effects of long-term FGF21 administration on the heart under the FGF21-resistant condition in obese, insulin-resistant rats have not been investigated. We hypothesized that long-term FGF21 administration reduces FGF21 resistance and insulin resistance and attenuates cardiac dysfunction in obese, insulin-resistant rats. Methods: Eighteen rats were fed on either a normal diet (n=6) or a high-fat diet (HFD; n=12) for 12weeks. Then, rats in the HFD group were divided into two subgroups (n=6 per subgroup) and received either the vehicle (HFV) or recombinant human FGF21 (rhFGF21, 0.1mgkg−1day−1; HFF) injected intraperitoneally for 28days. The metabolic parameters, inflammation, malondialdehyde (MDA), heart rate variability (HRV), left ventricular (LV) function, cardiac mitochondrial redox homoeostasis, cardiac mitochondrial fatty acid β-oxidation (FAO) and anti-apoptotic signalling pathways were determined. Results: HFV rats had increased dyslipidaemia, insulin resistance, plasma FGF21 levels, TNF-α, adiponectin and MDA, depressed HRV, and impaired LV and mitochondrial function. HFV rats also had decreased cardiac Bcl-2, cardiac PGC-1α and CPT-1 protein expression. However, FGF21 restored metabolic parameters, decreased TNF-α and MDA, increased serum adiponectin, and improved HRV, cardiac mitochondrial and LV function in HFF rats. Moreover, HFF rats had increased cardiac Bcl-2, cardiac PGC-1α and CPT-1 protein expression. Conclusion: Long-term FGF21 therapy attenuates FGF21 resistance and insulin resistance and exerts cardioprotection by improving cardiometabolic regulation via activating anti-apoptotic and cardiac mitochondrial FAO signalling pathways in obese, insulin-resistant rats.en_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.titleFibroblast growth factor 21 (FGF21) therapy attenuates left ventricular dysfunction and metabolic disturbance by improving FGF21 sensitivity, cardiac mitochondrial redox homoeostasis and structural changes in pre-diabetic ratsen_US
dc.typeJournalen_US
article.title.sourcetitleActa Physiologicaen_US
article.volume217en_US
article.stream.affiliationsChiang Mai Universityen_US
article.stream.affiliationsWenzhou Medical Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.